Neovii, Tel Aviv University partner for COVID-19 vaccine

By The Science Advisory Board staff writers

May 13, 2020 -- Israeli firm Ramot has inked a license agreement with Neovii, a Swiss-based biopharmaceutical company, for the research and development of a COVID-19 vaccine.

Ramot is Tel Aviv University's technology transfer company. University researchers have been working with coronaviruses for over 15 years, and shortly after SARS-CoV-2 emerged they began reconstituting a receptor binding motif as the basis for a new vaccine.

Under the agreement, Neovii will hold exclusive rights to develop and commercialize an epitope-based vaccine platform for the rapid discovery of a novel COVID-19 vaccine. The vaccine under development aims to reconstruct the coronavirus's receptor binding motif within the spike protein. The company will work to manufacture and deliver a commercial product to the general population on an accelerated timeline.

NIH leadership discusses COVID-19 vaccine collaborations
Public-private partnerships could help meet the unprecedented need to manufacture and distribute safe and effective COVID-19 vaccines around the globe,...
ABL Europe to manufacture Themis SARS-CoV-2 vaccine in France
Biopharmaceutical company Themis and contract development and manufacturing organization ABL Europe announced that they have signed an agreement to manufacture...
Inovio expands manufacturing for COVID-19 vaccine
Inovio has partnered with German contract manufacturer Richter-Helm BioLogics to produce large-scale quantities of Inovio's investigational DNA vaccine.

Copyright © 2020

Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter